10x Genomics (TXG)
(Delayed Data from NSDQ)
$27.59 USD
+0.69 (2.57%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.92 +0.33 (1.20%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth A Momentum B VGM
10x Genomics (TXG) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$50.84 | $70.00 | $21.50 | 89.00% |
Price Target
Based on short-term price targets offered by 16 analysts, the average price target for 10x Genomics comes to $50.84. The forecasts range from a low of $21.50 to a high of $70.00. The average price target represents an increase of 89% from the last closing price of $26.90.
Analyst Price Targets (16)
Broker Rating
10x Genomics currently has an average brokerage recommendation (ABR) of 1.74 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 17 brokerage firms. The current ABR compares to an ABR of 1.66 a month ago based on 16 recommendations.
Of the 17 recommendations deriving the current ABR, 11 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 64.71% and 5.88% of all recommendations. A month ago, Strong Buy made up 68.75%, while Buy represented 6.25%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 11 | 11 | 11 | 11 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 4 | 4 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 1.74 | 1.74 | 1.66 | 1.66 | 1.66 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/15/2024 | CIBC World Markets Corp. | Bryce Adams | Not Available | Hold |
12/14/2023 | Guggenheim Securities | Subbu Nambi | Not Available | Strong Buy |
12/1/2023 | BMO Capital Markets | Kevin O'Halloran | Not Available | Strong Buy |
11/6/2023 | William Blair | Matt Larew | Hold | Hold |
9/19/2023 | Canaccord Genuity | Kyle Mikson | Strong Buy | Strong Buy |
9/1/2023 | Stephens | Mason Carrico | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.74 |
ABR (Last week) | 1.74 |
# of Recs in ABR | 17 |
Average Target Price | $50.84 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.46 |